Trial: REZILIENT3 (REsearching ZIpaLertinib In…

Trial Details

Sponsor: Taiho Oncology, Inc. (industry)

Phase: 3

Start date: June 30, 2023

Planned enrollment: 272

Show Summary from Sponsor

The purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.

More details:

This study will evaluate the efficacy and safety of zipalertinib in combination with standard chemotherapy with pemetrexed and a platinum agent (either carboplatin or cisplatin) in patients with previously untreated, locally advanced or metastatic nonsquamous NSCLC harboring EGFR ex20ins mutations. The study will be conducted in two parts: * Part A: Safety lead-in to determine the recommended dose of zipalertinib in combination with standard chemotherapy pemetrexed and a platinum agent (either carboplatin or cisplatin) to be studied in Part B of the study. * Part B: Randomized, controlled, open-label, multinational Phase 3 study to assess the efficacy and safety of zipalertinib in combination with standard chemotherapy with pemetrexed and a platinum agent (either carboplatin or cisplatin) compared to standard chemotherapy alone. Patients randomized to the chemotherapy-only treatment arm in Part B may receive treatment with zipalertinib as monotherapy after BICR-assessed progressive disease (PD) is documented (optional "crossover arm"). An independent data monitoring committee (IDMC) will be established to monitor interim safety Data. A treatment cycle is defined as 21 days for both parts of the study. Part A: Safety Lead-In The primary objective of Part A is to determine the recommended dose of zipalertinib administered in combination with pemetrexed and a platinum agent (either carboplatin or cisplatin) to be studied in the Phase 3 portion of this study. Approximately 6-12 patients will receive zipalertinib administered at an initial dose of zipalertinib PO BID (Dose Level 1) in combination with pemetrexed and carboplatin or cisplatin on a 21-day cycle. Patients may continue to receive study treatment until documentation of progressive disease (PD) or until other withdrawal criteria are met, whichever comes first. Patients will be enrolled using a rolling-6 design,35 and the determination of the dose of zipalertinib to be used in Part B of the study will be informed by the incidence of dose-limiting toxicities (DLTs) observed during Cycle 1. Part B: Phase 3 Enrollment into the Phase 3 portion of the study will begin following completion of Part A. Approximately 260 patients will be randomized on a 1:1 basis to receive pemetrexed and a platinum agent (either carboplatin or cisplatin) with or without zipalertinib on a 21-day cycle. Carboplatin or cisplatin will be administered for 4 cycles. Patients may continue to receive zipalertinib (experimental study arm) and pemetrexed (both study arms) until documentation of PD or until other withdrawal criteria are met, whichever comes first.

Investigational Drug AI Analysis

Show for: TAS6417 (CLN-081, zipalertinib)

Overview

Zipalertinib, also known as CLN-081 or TAS6417, is an investigational oral tyrosine kinase inhibitor (TKI) targeting non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. These mutations are associated with resistance to conventional EGFR TKIs, presenting a significant therapeutic challenge.

Mechanism of Action

Zipalertinib is designed to selectively inhibit EGFR exon 20 insertion mutations while sparing wild-type EGFR. This selectivity aims to reduce off-target effects commonly associated with EGFR inhibition, such as rash and diarrhea. The drug's novel pyrrolopyrimidine scaffold enhances its binding affinity to mutant EGFR, leading to potent inhibition of tumor cell growth in preclinical models. (pubmed.ncbi.nlm.nih.gov)

Efficacy

In a phase 1/2a clinical trial involving 73 heavily pretreated patients with recurrent or metastatic NSCLC harboring EGFR exon 20 insertions, zipalertinib demonstrated promising antitumor activity. The confirmed objective response rate (ORR) across all dose levels was 38.4%, with all responses being partial. Specifically, at the 100 mg twice-daily dose, the ORR was 41%. The median progression-free survival (PFS) for all patients was 10 months, with a median duration of response (DOR) of 10 months. (pubmed.ncbi.nlm.nih.gov)

In a subsequent phase 2b study (REZILIENT1), zipalertinib continued to show efficacy in patients who had progressed after prior treatments, including amivantamab. Among 30 evaluable patients, the confirmed ORR was 40%, with a disease control rate (DCR) of 90%. The median PFS was 9.7 months, and the median DOR was not yet estimable at the time of reporting. (dnews.com)

Safety

Zipalertinib has demonstrated a manageable safety profile. In the phase 1/2a study, the most common treatment-related adverse events (TRAEs) were rash (80%), paronychia (32%), diarrhea (30%), and fatigue (21%). Notably, no grade 3 or higher rash or diarrhea occurred at doses of 100 mg twice daily or below. Grade 3 or higher TRAEs were observed in 23% of patients, with anemia being the most common (10%). (pubmed.ncbi.nlm.nih.gov)

In the phase 2b study, the safety profile remained consistent. The most common TRAEs (≥10%) included rash (38%), paronychia (36%), anemia (24%), dry skin (20%), dermatitis acneiform (16%), nausea (16%), and stomatitis (11%), with the majority being grade 1 or 2. No grade 4 or 5 TRAEs were reported. (dnews.com)

More Resources

Trial ID: NCT05973773

More trial details at ClinicalTrials.gov

Show News & AI Analysis

HealthScout AI Analysis

Goal: To evaluate the efficacy and safety of zipalertinib in combination with standard first-line platinum-based chemotherapy versus chemotherapy alone in patients with previously untreated, locally advanced or metastatic nonsquamous NSCLC harboring EGFR exon 20 insertion mutations.

Patients: Adult patients (≥18 years) with pathologically confirmed, locally advanced or metastatic nonsquamous non-small cell lung cancer, documented EGFR exon 20 insertion mutations, who have not received prior systemic therapy for advanced disease, with ECOG performance status 0 or 1. Patients with stable, treated brain metastases are eligible.

Design: This is a randomized, controlled, open-label, global phase 3 study. After an initial safety lead-in (Part A, to determine recommended dose), approximately 260 patients will be randomized 1:1 in Part B to chemotherapy plus zipalertinib or chemotherapy alone. Crossover to zipalertinib monotherapy is allowed in the control arm at progression. All patients receive treatment in 21-day cycles until disease progression or other withdrawal criteria are met.

Treatments: The investigational drug zipalertinib (TAS6417, also known as CLN-081) is an oral, irreversible EGFR tyrosine kinase inhibitor specifically targeting EGFR exon 20 insertion mutations with enhanced mutant vs wild-type EGFR selectivity. In a phase 1/2a trial, zipalertinib demonstrated a confirmed partial response rate of approximately 38-41% and a median progression-free survival up to 12 months, with a favorable safety profile relative to other EGFR TKIs. In this trial, it is being studied in combination with pemetrexed and a platinum agent (carboplatin or cisplatin), which collectively represent the current standard first-line chemotherapy regimen for nonsquamous NSCLC.

Outcomes: Primary endpoints include the rate and severity of treatment-emergent adverse events and progression-free survival by blinded independent central review. Additional primary outcomes in the safety lead-in include dose-limiting toxicities during cycle 1. Key secondary endpoints include objective response rate, disease control rate, duration of response, overall survival, intracranial response and duration, quality of life (EORTC QLQ-C30, EQ-5D-3L, NSCLC-SAQ), and pharmacokinetic parameters.

Burden on patient: The trial imposes a moderate patient burden. Requirements include regular clinic visits for administration of intravenous chemotherapy every 21 days for at least four cycles, daily oral administration of zipalertinib for those in the investigational arm, periodic imaging for response assessment (consistent with standard care), and additional blood draws for pharmacokinetics, especially in the lead-in cohort. There is no mandated fresh biopsy, but archival tissue submission for molecular confirmation is required. Quality-of-life questionnaires and symptom assessments are part of routine visits. The overall visit and testing schedule is generally similar to other phase 3 NSCLC trials, although the initial lead-in cohort will experience more intensive monitoring and PK sampling.

Eligibility

Show Criteria

Inclusion-

1. Provide written informed consent.

2. ≥18 years of age (or meets the country's regulatory definition for legal adult age, whichever is greater).

3. Pathologically confirmed, locally advanced or metastatic nonsquamous NSCLC

4. Has not received any prior systemic treatment for their locally advanced or metastatic nonsquamous NSCLC. Prior adjuvant/neoadjuvant treatment received \>6 months prior to first dose of study treatment is allowed for early-stage

NSCLC. Prior monotherapy with an approved EGFR TKI (ie, gefitinib, erlotinib, afatinib, dacomitinib, or osimertinib) as nonstandard first-line therapy for the treatment of locally advanced or metastatic disease is allowed if all of the following criteria are met:

1. Treatment duration did not exceed 8 weeks;

2. Lack of disease response was documented (radiographically) by an increase in tumor burden (a copy of the computerized tomography \[CT\] report showing increase in tumor burden from baseline should be submitted);

3. Associated toxicities have resolved to baseline; and

4. The EGFR TKI was discontinued at least 2 weeks or 4 half-lives prior to randomization, whichever is longer.

Prior therapy with EGFR TKI agents targeting exon20ins mutations including amivantamab, mobocertinib, sunvozertinib, furmonertinib, and poziotinib is not allowed.

5. Documented EGFR mutation status, as determined by local testing performed at a CLIA certified (US) or accredited (outside of the US) local laboratory, defined as follows:

1. Part A: EGFR ex20ins or other uncommon single or compound EGFR mutation

2. Part B: EGFR ex20ins mutation

6. Archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFR mutation status and, where possible, other biomarkers. Patients with insufficient tissue (details provided in laboratory manual) may be eligible following discussion with the sponsor; a fresh biopsy will not be required.

7. Patients with brain metastasis(es) who have previously received definitive local treatment and have stable central nervous system (CNS) disease (defined as being neurologically stable and off corticosteroid for at least 2 weeks prior to enrollment) are eligible. If brain metastases are diagnosed on screening imaging, the patient may be rescreened for eligibility after definitive treatment.

b. Asymptomatic brain metastases ≤2 cm in size can be eligible for inclusion if, in the opinion of the Investigator, immediate definitive treatment is not indicated.

8. At least one measurable lesion as determined per RECIST 1.1 for patients enrolling to Part B. Patients enrolling to Part A may be enrolled without measurable disease.

9. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

10. Adequate organ function, as defined by the laboratory value

11. Have a life expectancy of at least 3 months as assessed by the investigator.

12. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test prior to administration of the first dose of study treatment. Female patients are not considered to be of childbearing potential if they are postmenopausal (no menses for 12 months without an alternative medical cause) or permanently sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).

13. Both males and females of reproductive potential must agree to use effective birth control during the study prior to the first dose and for 6 months after the last dose of study treatment or longer, based on local requirements.

Exclusion -

1. Is currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged not to be scientifically or medically compatible with this study.

2. Prior treatment with any of the following within the specific time frame specified:

1. Zipalertinib (TAS6417/CLN-081) at any time.

2. Thoracic radiotherapy ≤28 days, palliative radiation of nonthoracic disease ≤14 days, or palliative radiation of a single lesion ≤7 days prior to first dose of study treatment.

3. Major surgery (excluding placement of vascular access) ≤28 days prior to first dose of study treatment.

4. All prescribed medication, over-the-counter medication, vitamin preparations and other food supplements, or herbal medications that are strong or moderate CYP3A4 inducers or inhibitors within 7 days prior to first dose.

3. Have any unresolved toxicity of Grade ≥2 from previous anticancer treatment in the neoadjuvant or adjuvant setting, except for Grade 2 alopecia or skin pigmentation. Patients with other chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the investigator and Sponsor.

4. Past medical history of interstitial lung disease, treatment-related pneumonitis (any grade), or any evidence of clinically active interstitial lung disease.

5. Impaired cardiac function or clinically significant cardiac disease, including any of the following:

1. History of congestive heart failure (CHF) Class III/IV according to the New York Heart Association (NYHA) Functional Classification .

2. Serious cardiac arrhythmias requiring treatment.

3. Resting corrected QT interval (QTc) \>470 msec calculated using Fridericia's formula (QTcF).

6. Unable to swallow tablets or has any disease or condition that may significantly affect gastrointestinal (GI) absorption of zipalertinib (such as inflammatory bowel disease, malabsorption syndrome, or prior GI resection).

7. History of another primary malignancy ≤2 years prior to the date of first dose of study treatment unless at least one of the following criteria are met:

1. Adequately treated basal or squamous cell carcinoma of the skin

2. Cancer of the breast or cervix in situ

3. Previously treated malignancy, if all treatment for that malignancy was completed at least 2 years prior to first dose of study treatment, and no current evidence of disease

4. Concurrent malignancy determined to be clinically stable and not requiring tumor directed treatment

8. Known history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) that is unstable or not controlled with treatment.

9. History of COVID-19 infection within 4 weeks prior to enrolment and/or have persistent, clinically significant pulmonary symptoms related to prior COVID-19 infection.

10. Active bleeding disorders.

11. Known hypersensitivity to the ingredients in zipalertinib or any drugs similar in structure or class. To platinum-containing drugs (ie, cisplatin, carboplatin), pemetrexed, or any known excipients of these drugs. b. Contraindications toning drugs (ie, cisplatin, carboplatin) or pemetrexed according to the respective local labels.

12. History of leptomeningeal disease and spinal cord compression.

13. Is unable or unwilling to take dexamethasone, folic acid, and/or vitamin B12 supplementation during treatment with pemetrexed.

14. Is pregnant or lactating or planning to become pregnant

Houston, Texas, 77030, United States

No email / No phone

Status: Recruiting

Trial Details

Show Summary from Sponsor

More details:

Investigational Drug AI Analysis

Show for: TAS6417 (CLN-081, zipalertinib)

Overview

Mechanism of Action

Efficacy

Safety

Further Reading

More Resources

Show News & AI Analysis

HealthScout AI Analysis

Eligibility

Show Criteria

Sites (114)

Universitair Ziekenhuis Leuven - Campus Gasthuisberg

Algemeen Ziekenhuis Maria Middelares

Algemeen Ziekenhuis Delta - Campus Menen

Algemeen Ziekenhuis Delta - Campus Rumbeke

Centro Regional Integrado de Oncologia

Hospital São Lucas da PUCRS

Clínica Neoplasias Litoral

Hospital Amaral Carvalho

Multi-profile Hospital for Active Treatment Uni Hospital

University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna-ISUL

William Osler Health System - Brampton Civic Hospital

Princess Margaret Cancer Centre

Les Hôpitaux Universitaires de Strasbourg

Hôpital Côte De Nacre

Institut Curie

Hôpital Ambroise-Paré

Centre Hospitalier Universitaire Limoges

Hôpital Haut-Lévêque

Centre Hospitalier Le Mans

Gustave Roussy

Asklepios Klinik Altona

Universitätsklinikum Gießen und Marburg - Gießen

Universitätsklinikum Regensburg

LMU Klinikum - Campus Innenstadt

Metropolitan General

General Hospital for Thoracic Diseases Sotiria

University General Hospital of Patras

Metropolitan Hospital

University General Hospital of Larissa

BioClinic Thessaloniki

Shaare Zedek Medical Center

Emek Medical Center

Hadassah University Hospital Ein Kerem

Tel Aviv Sourasky Medical Center

Assuta Hospital - Ramat HaHayal

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST

Azienda Ospedaliero - Universitaria di Modena

Azienda Ospedaliera Universitaria Integrata Verona

Azienda Unità Sanitaria Locale della Romagna

Fondazione IRCCS Policlinico San Matteo

Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele

Aichi Cancer Center

Hirosaki University Hospital

Kyushu Cancer Center

Kanagawa Cardiovascular and Respiratory Center

Kitasato University Hospital

Saiseikai Kumamoto Hospital

Sendai Kousei Hospital

Okayama University Hospital

National Hospital Organization Kinki-Chuo Chest Medical Center

Kansai Medical University Hospital

Keio University Hospital

Cancer Institute Hospital of JFCR

Osaka City General Hospital

Osaka Prefectural Hospital Organization - Osaka International Cancer Institute

Kanazawa University Hospital

Catholic University of Korea Saint Vincent's Hospital

Ajou University Hospital

Gyeongsang National University Hospital

Inha University Hospital

Korea University Anam Hospital

Korea University Guro Hospital

Clínica Integral Internacional de Oncología S de RL de CV

FAICIC Clínical Research